Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)

American Heart Journal

Volumn 160, Issue 1, 2010, Pages 65-72

  Leonardi, Sergio ^a,b   Rao, Sunil V ^a   Harrington, Robert A ^a   Bhatt, Deepak L ^c   Gibson, C Michael ^d   Roe, Matthew T ^a   Kochman, Janusz ^e   Huber, Kurt ^f   Zeymer, Uwe ^g   Madan, Mina ^h   Gretler, Daniel D ⁱ   McClure, Matthew W ⁱ   Paynter, Gayle E ^a   Thompson, Vivian ^a   Welsh, Robert C ^j  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

^f Cardiology and Emergency Medicine   (Austria)

^g Institut fur Herzinfarktforschung   (Germany)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ Portola Pharmaceuticals Inc   (United States)

^j UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ELINOGREL; PRT 060128; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIAC PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LOADING DRUG DOSE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; QUINAZOLINONES; RECEPTORS, PURINERGIC P2; SULFONAMIDES; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; TROPONIN; YOUNG ADULT;

EID: 77955677366     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.04.008     Document Type: Article

References (28)

1. Yusuf S., Zhao F., and Mehta S.R. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
2. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1996 1329 1339
3. Bhatt D.L., Fox K.A.A., and Hacke W. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 2006 1706 1717
4. Trenk D., Hochholzer W., and Fromm M.F. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934
5. Hollopeter G., Jantzen H.M., and Vincent D. Identification of the platelet ADP receptor targeted by antithrombotic drugs Nature 409 2001 202 207
6. Savi P., Pereillo J.M., and Uzabiaga M.F. Identification and biological activity of the active metabolite of clopidogrel Thromb Haemost 84 2000 891 896
7. Pereillo J.M., Maftouh M., and Andrieu A. Structure and stereochemistry of the active metabolite of clopidogrel Drug Metab Dispos 30 2002 1288 1295
8. Angiolillo D.J., Fernandez-Ortiz A., and Bernardo E. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel Arterioscler Thromb Vasc Biol 26 2006 1895 1900
9. Hulot J.S., Bura A., and Villard E. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
10. Hochholzer W., Trenk D., and Bestehorn H.P. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement J Am Coll Cardiol 48 2006 1742 1750
11. Sibbing D., Stegherr J., and Latz W. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J 30 2009 916 922
12. Gurbel P.A., Bliden K.P., and Hiatt B.L. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
13. Simon T., Verstuyft C., and Mary-Krause M. Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
14. Anderson J.L., Adams C.D., and Antman E.M. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College of Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J Am Coll Cardiol 50 2007 e1 e157
15. Berger J.S., Roe M.T., and Gibson C.M. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial Am Heart J 158 2009 998 1004
16. Steinhubl S.R., Oh J.J., and Oestreich J.H. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect Thromb Res 121 2008 527 534
17. Thygesen K., Alpert J.S., White H.D. on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction Universal definition of myocardial infarction Circulation 116 2007 2634 2653
18. Cutlip D.E., Windecker S., and Mehran R. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
19. Roe M.T., Christenson R.H., and Ohman E.M. A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes Am Heart J 146 2003 993 998
20. Talarico G.P., Brancati M., and Burzotta F. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study J Cardiovasc Med 10 2009 245 251
21. Jeremias A., Kleiman N.S., and Nassif D. Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the evaluation of drug eluting stents and ischemic events registry Circulation 118 2008 632 638
22. Mehta S.R., Yusuf S., and Peters R.J.G. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
23. Wiviott S.D., Braunwald E., and McCabe C.H. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
24. Wallentin L., Becker R.C., Budaj A. for the PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
25. Harrington R.A., Stone G.W., McNulty S. for the CHAMPION PCI Investigators Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 2009 2318 2329
26. Bhatt D.L., Lincoff A.M., Gibson C.M. for the CHAMPION PLATFORM Investigators Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 2009 2330 2334
27. Steinhubl S.R., Berger P.B., and Mann J.T. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention JAMA 288 2002 2411 2421
28. Gurbel P.A., Bliden K.P., and Antonino M.J. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to cyp 2c19*2 genotype: first experience in patients J Thromb Haemost 8 2010 43 53